Health News

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that independent researchers today presented results showing that XOMA’s antibody to interleukin-1 beta (IL-1 beta), XOMA 052, was highly effective in reducing production of a protein that supports the proliferation of cancerous human myeloma cells in vitro.

Read more

Filed under: Pharmacy News
Tags: Pharmacy, Protein

Related posts

• ZyStor Therapeutics, Inc. Cleared To Begin Clinical Trial For Targeted Protein Therapeutic For The Treatment Of Pompe Disease (0)
  ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, [...]
  
  
• Zyngenia completes $15M Series A financing extension from NEA (0)
  Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, [...]
  
  
• XTEN Data From Amunix And Versartis Featured In Nature Biotechnology As A Novel Platform For Increasing Serum Half-Life Of Protein Therapeutics (0)
  Amunix, Inc. and Versartis, Inc. announced today that the scientific journal Nature Biotechnology has published a comprehensive paper entitled "A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner." The paper (http://dx.doi.org/10.1038/nbt. Read more [tags] Pharmacy News [/tags]
  
  
• Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation (0)
  Merz Pharmaceuticals announced that data from stability and clinical studies evaluating Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash. The U.S... Read more [tags] Pharmacy News [/tags]
  
  
• Xcellerex and Itero collaborate in production of an undisclosed therapeutic protein (0)
  Xcellerex, Inc. and Itero Biopharmaceuticals, Inc. announced today that they have signed a Letter of Intent to enter into a strategic collaboration for the production of Itero’s lead product, an undisclosed commercially differentiated therapeutic protein. Itero will initiate technology transfer for the product to Xcellerex immediately. Read more [tags] Pharmacy News [/tags]